AIAIAI.FYI LIVE

Isomorphic Labs raises $5 billion, its second billion-dollar round in six months

Greenoaks and Sequoia co-led the round, with Andreessen Horowitz joining as a new backer, while the Alphabet unit still has no approved drug.

What happened

Isomorphic Labs is Alphabet's AI drug discovery company. It has raised $5 billion from investors. It raised $2.1 billion in May 2026, so this is its second huge round in six months.

Why it matters to you

The money funds AI tools meant to design medicines faster. If they work, new drugs could reach patients sooner, but none has been approved yet.

The takeaway

Investors are betting big on AI-designed drugs, but the company has no approved drug so far.

What it means for you

If you build software

IsoDDE is the in-house platform to track, with the company claiming it improves on AlphaFold 3 for binding and docking site prediction.

If you run a business

Pharma partners Novartis, Eli Lilly and Johnson & Johnson already work with Isomorphic, so AI-led drug design is entering established partnerships.

If you invest

Two rounds totaling $7.1 billion in six months show heavy capital flowing in, yet the company has no approved drug to show for it.

Get stories like this every morning